MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. The company is headquartered in Planegg, Bayern and currently employs 86 full-time employees. The company went IPO on 2000-06-30. The firm focuses on the development of personalized T cell-based immunotherapies. The company develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The firm operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.
Follow-Up Questions
What is the price performance of MDGEF stock?
The current price of MDGEF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Medigene AG?
Medigene AG belongs to Biotechnology industry and the sector is Health Care
What is Medigene AG market cap?
Medigene AG's current market cap is $0
Is Medigene AG a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for Medigene AG, including 0 strong buy, 0 buy, 3 hold, 4 sell, and 0 strong sell
